Fig. 2.

Profile of predominant cytokines, memory T cell and humoral response. a Development of detectable cytokines in serum of the multiple myeloma (MM) patient over time. b Comparison of detected cytokine concentrations between SARS-CoV-2-infected MM patient and male COVID-19 patients with severe (n = 1, 52 years old) and moderate (n = 1, 65 years old) symptoms at day 21 ± 3 days after diagnosis of SARS-CoV-2 infection. The dotted line indicates the values measured in a male healthy control (n = 1, < 50 years old). Ct-values of SARS-CoV-2-specific PCR at day + 11 after COVID-19 diagnosis are indicated underneath the respective patients. At day + 22, all patients were found to be negative for SARS-CoV-2. c, d IFN-γ response of cryopreserved, thawed, and overnight rested PBMCs to SARS-CoV-2 peptide mix measured by ELISpot assay. Comparison of PBMCs from MM patient isolated at day + 44 and + 174 with an age-matched, male convalescent patient (n = 1, 52 years old) at day + 44 after COVID-19 diagnosis and the same healthy male (n = 1, < 50 years) used for the other analyses. Quantification of spot forming units (SFU)/3 × 105 PBMCs was normalized to the unspecific response (SFU/3 × 105 PBMCs without stimulus) (c) and representative images of the wells (d) are displayed. Values are indicated with mean and standard derivation. e Quantitative detection of SARS-CoV-2 Spike protein IgG in the MM patient’s serum to different time points after COVID-19 diagnosis in comparison to an age-matched male convalescent patient (n = 1, 52 years old, mild COVID-19 symptoms, day + 44 after diagnosis). f Maximal dilution factor of serum by which SARS-CoV-2 neutralization was mediated in a plaque reduction neutralization test (PRNT). Comparison of the MM patient’s serum to different time points after COVID-19 diagnosis to an age-matched male convalescent patient (n = 1, 52 years old, mild COVID-19 symptoms, day + 44 after diagnosis)